Bussen S, Rempen A, Caffier H
Universitätsfrauenklinik, Würzburg.
Zentralbl Gynakol. 1995;117(5):253-9.
The concentration of total cathepsin D in tumor cytosol was measured in 300 patients with primary breast cancer treated at the Women's University Hospital in Würzburg between 10/86 and 9/92. Patients were followed for a median of 28 months. The level of cathepsin D was correlated with estrogen receptor status and tumor size but seemed to be independent of progesterone receptor status, histological grading, patient's age, axillary lymph node involvement and primary distant metastases. Overall survival, disease-free survival and metastases-free survival did not differ between patients with cathepsin D-levels above the median value of 47 pmol/mg of protein and patients with cathepsin D-concentration below 47 pmol/mg. Patients with node-negative disease and low cathepsin D-levels (< or = 47 pmol/mg) had a longer disease-free survival than those with cathepsin D-concentration > 47 pmol/mg (p < 0.05). Our findings could not confirm cathepsin D as a useful additional prognostic marker in all breast cancer patients. In the low-risk collective the measurement of total cathepsin D may be significant by isolating subgroups with a poorer prognosis who might benefit from adjuvant therapy.
对1986年10月至1992年9月期间在维尔茨堡大学妇女医院接受治疗的300例原发性乳腺癌患者的肿瘤细胞溶质中组织蛋白酶D的总浓度进行了测量。患者的中位随访时间为28个月。组织蛋白酶D的水平与雌激素受体状态和肿瘤大小相关,但似乎与孕激素受体状态、组织学分级、患者年龄、腋窝淋巴结受累情况及远处原发性转移无关。组织蛋白酶D水平高于蛋白质中位数47 pmol/mg的患者与组织蛋白酶D浓度低于47 pmol/mg的患者相比,总生存期、无病生存期和无转移生存期并无差异。淋巴结阴性且组织蛋白酶D水平低(≤47 pmol/mg)的患者比组织蛋白酶D浓度>47 pmol/mg的患者无病生存期更长(p<0.05)。我们的研究结果无法证实组织蛋白酶D可作为所有乳腺癌患者有用的额外预后标志物。在低风险人群中,通过分离出预后较差且可能从辅助治疗中获益的亚组,测量总组织蛋白酶D可能具有重要意义。